Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors
Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …
A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay
Lung cancer (LC) is the most common cancer-related death globally, and many efforts have
been made to improve the patient care of LC patients, as well as the development of efficient …
been made to improve the patient care of LC patients, as well as the development of efficient …
The roles of MicroRNA in lung cancer
KL Wu, YM Tsai, CT Lien, PL Kuo, JY Hung - International journal of …, 2019 - mdpi.com
Lung cancer is the most devastating malignancy in the world. Beyond genetic research,
epigenomic studies—especially investigations of microRNAs—have grown rapidly in …
epigenomic studies—especially investigations of microRNAs—have grown rapidly in …
Current and future perspectives of PD‐1/PDL‐1 blockade in cancer immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has
yielded great success in recent years. Among immunotherapeutic agents, immune …
yielded great success in recent years. Among immunotherapeutic agents, immune …
Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
Background To date, standardising clinical predictive biomarkers for assessing the response
to immunotherapy remains challenging due to variations in personal genetic signatures …
to immunotherapy remains challenging due to variations in personal genetic signatures …
Recent findings in the regulation of programmed death ligand 1 expression
X Shen, L Zhang, J Li, Y Li, Y Wang, ZX Xu - Frontiers in immunology, 2019 - frontiersin.org
With the recent approvals for the application of monoclonal antibodies that target the well-
characterized immune checkpoints, immune therapy shows great potential against both …
characterized immune checkpoints, immune therapy shows great potential against both …
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
T Rajakumar, R Horos, J Jehn, J Schenz… - NPJ Precision …, 2022 - nature.com
Immunotherapies have recently gained traction as highly effective therapies in a subset of
late-stage cancers. Unfortunately, only a minority of patients experience the remarkable …
late-stage cancers. Unfortunately, only a minority of patients experience the remarkable …
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
T Singh, MF Hassanabad, AF Hassanabad - Biochimica et Biophysica Acta …, 2021 - Elsevier
Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): which are the involved players?
G Lamberti, M Sisi, E Andrini, A Palladini, F Giunchi… - Cancers, 2020 - mdpi.com
Simple Summary Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in
non-small cell lung cancer patients. These treatments are more effective the higher the …
non-small cell lung cancer patients. These treatments are more effective the higher the …
Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment
Cancer immunotherapy represents a promising new era in cancer management due to the
relatively high safety margins and selectivity, compared to the classical cancer …
relatively high safety margins and selectivity, compared to the classical cancer …